Why Is Oxford Nanopore Up Today?
Oxford Nanopore Technologies shares rose 8.02% today to 215.4p, a gain of 16p, according to the market data provided. The move values the group at around £1.95 billion and extends a powerful run that saw the shares close up more than 9% at 199.4p in the previous session.
There was no major regulatory announcement behind today's gain. Instead, the rally reflects building momentum after half-year results in August convinced investors that the company's new Leadership has a credible route to profitability.
Key Highlights
First-half Revenue rose 10.5% on a reported basis to £116.7 million. The loss of £22.1 million was smaller than analysts had expected, and management kept its guidance for a breakeven position in the 2027 financial year.
New chief executive Francis Van Parys set out a longer-term ambition to build a Business generating more than $1 billion of annual revenue. The shares jumped sharply after the update, even though revenue expectations had been trimmed in July.
Over the two weeks to 28 September, the shares rose more than 18% and have since set fresh 52-week highs.
About Oxford Nanopore Technologies
Oxford Nanopore develops nanopore-based sensing technology that reads DNA and RNA in real time. Its devices range from portable MinION units to high-throughput PromethION systems, supported by recurring consumable sales.
For LSE:ONT, the key indicators are revenue growth, gross margin, operating costs, cash burn and progress in clinical, biopharma and applied industrial markets.
Key Reasons Behind Today's Uptick
Investors are rewarding the shift from growth at any cost to disciplined growth. The interim update highlighted Margin expansion, lower operating expenses and stronger device sales, which together point towards the breakeven goal.
Sentiment has also been helped by insider buying, with director Nick Keher purchasing shares in early September. On 29 September the company said it had joined RISE, a global rare-disease genomics programme, which supports its push into clinical use.
Momentum buying is now amplifying the move as the shares break into new territory.
Diversification Beyond Research
Oxford Nanopore's growth outside academic research is central to the story. In 2025, clinical revenue grew 60%, biopharma 30% and applied industrial 27%, while research grew 15% despite funding pressure. Expanding into these end markets reduces dependence on volatile university and government budgets.
Balance Sheet
The company ended 2025 with net cash of around £302 million. That provides a meaningful runway, but the business remains loss-making, so cash burn must continue to fall to avoid the need for fresh capital.
Growth Catalysts
The most important catalyst is delivery of breakeven in 2027. Achieving that would remove the need for further fundraising and allow investors to value the business on future Earnings rather than hope.
Clinical adoption is another major lever. As long-read sequencing gains acceptance in rare disease diagnosis, cancer research and infectious disease testing, recurring consumable revenue should rise. The PromethION range, which grew strongly last year, is particularly important because each installed device drives ongoing flow-cell sales.
Finally, a successful execution of the new CEO's plan could attract a broader base of healthcare investors who previously avoided the stock because of repeated guidance changes.
Risks
The biggest risk is that profitability slips again. Revenue was trimmed earlier in the year, and competition from larger sequencing groups remains intense.
The valuation has also run ahead of broker targets. MarketBeat data shows an average analyst price target of about 198.6p, below today's price.
Iran War and Its Impact on Oxford Nanopore
The Iran conflict affects Oxford Nanopore mainly through inflation, interest rates and research budgets rather than direct exposure. Brent Crude traded around $105 a barrel on 29 September, and higher energy costs could keep rates elevated, which tends to pressure valuations of loss-making growth companies.
On the other hand, heightened biosecurity and pathogen surveillance priorities could support Demand for rapid, portable sequencing.
Valuation
At 215.4p, Oxford Nanopore trades on a high multiple of revenue relative to its current losses. The valuation assumes it hits breakeven in 2027 and then scales towards its $1 billion revenue ambition. Any delay could trigger a sharp pull-back.
What Investors Should Watch Next
Investors should focus on revenue growth, gross margins, cash burn, clinical adoption and full-year guidance, along with any updates on major PromethION placements.
Conclusion
Oxford Nanopore's 8.02% rise today reflects growing confidence in its turnaround under new leadership. The technology is differentiated and end-market Diversification is working, but the shares now price in a great deal of future success.






Please wait processing your request...